4//SEC Filing
Ra Pharmaceuticals, Inc. 4
Accession 0001104659-16-153349
CIK 0001481512operating
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 4:51 PM ET
Size
24.5 KB
Accession
0001104659-16-153349
Insider Transaction Report
Form 4
MORGENTHALER VENTURE PARTNERS IX LP
10% Owner
Transactions
- Exercise of In-Money
Common Stock
2016-10-31$0.07/sh+63,019$4,411→ 80,161 total - Conversion
Common Stock
2016-10-31+486,919→ 2,482,308 total - Exercise of In-Money
Warrants to Purchase Common Stock
2016-10-31−63,019→ 0 totalExercise: $0.07Exp: 2022-04-01→ Common Stock (63,019 underlying) - Conversion
Series B-2 Preferred Stock
2016-10-31−3,408,439→ 0 total→ Common Stock (486,919 underlying) - Conversion
Common Stock
2016-10-31+523,438→ 1,995,389 total - Conversion
Series A Preferred Stock
2016-10-31−9,744,916→ 0 total→ Common Stock (1,392,130 underlying) - Sale
Common Stock
2016-10-31$13.00/sh−340$4,420→ 79,821 total - Conversion
Common Stock
2016-10-31+1,392,130→ 1,471,951 total - Purchase
Common Stock
2016-10-31$13.00/sh+263,538$3,425,994→ 2,745,846 total - Conversion
Series B-1 Preferred Stock
2016-10-31−3,664,071→ 0 total→ Common Stock (523,438 underlying)
Transactions
- Conversion
Common Stock
2016-10-31+523,438→ 1,995,389 total - Conversion
Common Stock
2016-10-31+486,919→ 2,482,308 total - Conversion
Series B-2 Preferred Stock
2016-10-31−3,408,439→ 0 total→ Common Stock (486,919 underlying) - Conversion
Common Stock
2016-10-31+1,392,130→ 1,471,951 total - Purchase
Common Stock
2016-10-31$13.00/sh+263,538$3,425,994→ 2,745,846 total - Exercise of In-Money
Warrants to Purchase Common Stock
2016-10-31−63,019→ 0 totalExercise: $0.07Exp: 2022-04-01→ Common Stock (63,019 underlying) - Conversion
Series B-1 Preferred Stock
2016-10-31−3,664,071→ 0 total→ Common Stock (523,438 underlying) - Sale
Common Stock
2016-10-31$13.00/sh−340$4,420→ 79,821 total - Conversion
Series A Preferred Stock
2016-10-31−9,744,916→ 0 total→ Common Stock (1,392,130 underlying) - Exercise of In-Money
Common Stock
2016-10-31$0.07/sh+63,019$4,411→ 80,161 total
Footnotes (5)
- [F1]The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. MMP IX disclaims beneficial ownership of the securities held by MVP IX except to the extent of its pecuniary interest therein.
- [F2]The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.
- [F3]Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
- [F4]Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
- [F5]Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.
Documents
Issuer
Ra Pharmaceuticals, Inc.
CIK 0001481512
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001481512
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 4:51 PM ET
- Size
- 24.5 KB